The China BioMed Innovation and Investment Conference (CBIIC), as a premier platform fostering high-level dialogue between the pharmaceutical and investment industries, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of the pharmaceutical industry, the CBIIC focuses on China’s latest policies in the pharmaceutical industry, explores the new trends of global pharmaceutical R&D, and trends in the investment and financing circle. The CBIIC is built as an authoritative, comprehensive, professional, and international high-level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises, and investors to discuss current trends of innovation and new strategies for investment and cooperation. On October 24–25, 2026, the 2026 CBIIC will convene once again. Focused on industrial transformation, frontier global pharmaceutical R&D trends, and evolving investment and financing dynamics, 2026 CBIIC will bring together leaders and experts from top leading research institutions, pharmaceutical companies, multinational corporations, and investment institutions at home and abroad, and conduct in-depth discussions on emerging trends in innovation-driven development, jointly explore new strategies for cross-border investment and collaboration, contributing insights to the resilient growth of the global pharmaceutical innovation ecosystem.

Established by PhIRDA, the CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX), Chinese Hospital Association (CHA), and Research and Development International (RDI), and has successfully convened 10 sessions from 2016 to 2025. Up to now, the CBIIC has attracted over 40,000 participants, 10,000 domestic and foreign pharmaceutical enterprises, and financial and investment institutions, and about 1,000 innovative projects at home and abroad have made roadshows. The One-on-One Partnering System received over 40,000 meeting requests and completed over 4,000 business meetings, achieving efficient connections and targeted collaboration between the global pharmaceutical innovation and investment communities. Besides serving as a premier platform for industry exchange and investment engagement, CBIIC has witnessed the debut of numerous groundbreaking innovations and facilitated a series of milestone cross-border transactions and strategic partnerships. Widely recognized as a “Bellwether” of China’s pharmaceutical innovation landscape and a “Litmus Test” for investment value, the CBIIC has won high attention and acclaim from industry and investment communities, and is hailed as “most popular cooperation platform for pharmaceutical innovation and investment in the Asia-Pacific region.”

I. A New Approach to Project Roadshows: More Focused, Broader in Scope, Technologically Advanced

The CBIIC remains committed to fostering the integration of capital and pharmaceutical innovation, invigorating early-stage technological innovation among domestic pharmaceutical innovators, and shaping an ecosystem conducive to high-quality development. Over the years, it has collaborated with stock exchanges, industry associations, international media, and think tanks to bring together the most promising and forward-looking innovation projects. By organizing a wide range of roadshows and forums, the CBIIC delves into critical topics including pharmaceutical policies, R&D, clinical development and investment, meeting the diverse needs of participants.

2026 CBIIC highlights key areas including AI-driven drug R&D, CGT, antibody drugs and XDCs, nucleic acid therapeutics and delivery technologies. The event balances cutting-edge technologies with subfields, and covers the entire innovation spectrum—from radiopharmaceuticals, PROTAC Technology, and peptide-based drugs to natural products, and include rare diseases, pediatric medicines, and international innovation projects as well. With sustained attention to clinical value and translational potential, the CBIIC systematically refines and categorizes roadshow topics to meet the practical needs of emerging biotech firms. It promotes precise matchmaking between enterprises and investors, facilitating a full-cycle innovation network that spans target identification, technology validation, clinical translation, and commercialization. CBIIC continues to serve as a high-efficiency dialogue platform that propels China’s biomedical innovation ecosystem toward greater internationalization.

With sustained attention to clinical value and translational potential, the CBIIC systematically refines and categorizes roadshow topics to meet the practical needs of emerging biotech firms. It promotes precise matchmaking between enterprises and investors, facilitating a full-cycle innovation network that spans target identification, technology validation, clinical translation, and commercialization. CBIIC continues to serve as a high-efficiency dialogue platform that propels China’s biomedical innovation ecosystem toward greater internationalization.

II. Engage with Leading Experts and Share Academic Insights

2026 CBIIC gathered prominent figures from national and governmental agencies, academicians, experts, scientists, entrepreneurs and investors. Distinguished KOLs included: He Wei, Vice Chairman of the Standing Committee of the 14th National People’s Congress (NPC) and Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party (CPWDP); Zeng Yixin, Vice Minister of the National Health Commission; Chen Deming, former Minister of Commerce; Shang Fulin, former Chairman of the China Banking Regulatory Commission (CBRC); Cao Xuetao, Vice-Chairman of Committee on Education, Science, Health and Sports of National Committee of the Chinese People’s Political Consultative Conference (CPPCC) , Academician of Chinese Academy of Engineering, Chief Engineer of National Science and Technology Major Project for Innovative Drug R&D; Yu Xubo, Chairman and Party Secretary of China General Technology (Group) Holding Co., Ltd; Wang Zhongmin, Chairman of the Shenzhen Institute of Financial Stability and Development and former Vice Chairman of the National Council for Social Security Fund; Zhu Min, Member of the Expert Committee of the China Center for International Economic Exchanges and former Deputy Managing Director of the International Monetary Fund (IMF); Liu Qian, Vice Chairman of the Education, Science, Culture and Public Health Committee of the National People’s Congress; Zhang Shuyang, President of Peking Union Medical College Hospital; Rao Zihe, Member of the Chinese Academy of Sciences (MCAS), Professor of Tsinghua University; Tian Zhigang, Academician of Chinese Academy of Engineering, Director of Institute of Immunology, University of Science and Technology of China; Huang Xiaojun, Chairman of Peking University Institute of Hematology, PUPH, Director of National Clinical Research Center for Hematologic Diseases; Chen Kaixian, Academician of Chinese Academy of Sciences (CAS), delivering insightful speeches, providing authoritative policy interpretations and the latest industry trends.

The CBIIC has received great support from prestigious institutions in China and around the world, including the Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences, China Pharmaceutical University and authoritative academic institutions; embassies and consulates of the United Kingdom, Canada, the Netherlands, Australia, Denmark, Singapore and other countries in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) and other international organizations including the Hong Kong Trade Development Council, Hong Kong Productivity Council, the HK Bio-Med Innotech Association, and BioCentury. In addition, financial institutions including the Chinese Securities Association of Hong Kong (CSAHK) and TMX Group have provided ongoing support. Moreover, J.P. Morgan has supported the CBIIC as the exclusive international financial institution sponsor for multiple consecutive years.

The 2026 CBIIC will continue to deepen cooperation with government departments and well-known institutions around the world, and invite industry leaders and top experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China’s capability on transformation and innovation in the pharmaceutical industry.

III. Efficient Innovation-to-Capital Matchmaking to Facilitate Rapid Transformation of Innovative Research

The CBIIC is dedicated to advancing the transformation of technological innovations, the latest global trends in investment and financing, and new policies in the pharmaceutical industry. It serves as a premier platform for sharing resources, exchanging information, and fostering mutually beneficial cooperation among all parties. By facilitating meaningful connections between investment institutes and innovative projects, financial services and the real economy, and technological breakthroughs and industry applications, the conference has created a comprehensive international platform that covers drug development, clinical practice, investment, production, and usage. This has sped up the integration of China’s pharmaceutical innovations with global standards, making the CBIIC a key platform for promoting China’s pharmaceutical policies and achievements internationally, attracting foreign investment, and supporting the global expansion of domestic innovations.

To facilitate effective communication and precise cooperation between domestic and international pharmaceutical innovators and investors and bridge the investment and financing, the 2026 CBIIC will continue to provide an One-on-One Partnering System, through which investors and roadshow speakers can efficiently search for potential partners and clients, initiate invitations, and schedule face-to-face and virtual meetings. All-round service of face-to-face and online communication and negotiation will be available for participants to seek potential opportunities and commercial values for further collaboration.

IV. Great Attention from Domestic and Global Media and Witness the Integration of Innovation and Investment

Since 2016, the CBIIC was supported by over ten well-known magazines and traditional media at home and abroad, including top leading international academic journal Nature, people.cn, Health News, China Pharmaceutical News, Caixin Weekly, International Financial News, Medicine Economic Reporter, Time Weekly, China Business News, and attracted new media and healthcare financial media including Xinhua Net, Global News, Phoenix New Media, PharmaBoardroom, Jiemian.com, 36 Kr, Cailian Press, to make real-time reports of the event and witness the integration of innovation and investment.

Under the great support of all parties, the CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circles, present pharmaceutical innovative achievements at home and abroad, and lead new investment trends. As the most influential annual grand conference in the Asia-Pacific region, the CBIIC will continue to play a leading role in the development of social capital and pharmaceutical innovation, create a more scientific and attractive investment environment, and contribute to China’s economic and social development to meet the clinical needs and advance the pursuit of Healthy China.